|
|
以胸痛为首发症状的惠普尔养障体肺部感染1例及文献回顾
|
Abstract:
惠普尔养障体(Tropheryma whipplei, TW)是一种革兰氏阳性放线菌，广泛存在于土壤、污水和外部环境中，同时以无症状病原体存在于人群中，属于条件致病菌。惠普尔病(Whipple disease, WD)是由TW感染引起的罕见的复杂性多系统损害性疾病，其主要影响消化系统、关节、神经系统及心血管系统。TW引起的肺部感染临床少见，其发病机制尚不明确，诊疗思路亦尚未统一。国内外关于TW肺炎的相关研究非常少，随着宏基因组下一代测序(Metagenomic next generation sequencing, mNGS)的普及，TW引发的肺部感染病例发现率较前有所增加。TW引发的WD具有临床症状不典型、病情进展迅速、死亡率高等特点，因此早期识别并规范化诊疗对于改善TW感染患者预后具有重要意义。本研究回顾性分析1例以间断胸痛为首发表现的TW肺部感染患者的临床资料，旨在为临床医师提供一定诊疗思路，现报道如下。
Tropheryma whipplei (TW) is a Gram-positive actinomycete that is widely present in soil, sewage and external environment, and also exists in humans as an asymptomatic pathogen. Whipple disease (WD) is a rare complex multi-system damaging disease caused by TW infection, which mainly affects the digestive system, joints, nervous system and cardiovascular system. Pulmonary infection caused by TW is rare in clinic, its pathogenesis is not clear, and the diagnosis and treatment ideas have not been unified. There are very few relevant studies on TW pneumonia at home and abroad. With the popularization of metagenomic next generation sequencing (mNGS), the detection rate of pulmonary infection caused by TW has increased. WD caused by TW is characterized by atypical clinical symptoms, rapid disease progression, and high mortality. Therefore, early identification and standardized diagnosis and treatment are of great significance for improving the prognosis of TW infected patients. This study retrospectively analyzed the clinical data of a case of TW pulmonary infection with intermittent chest pain as the first manifestation, aiming to provide certain diagnosis and treatment ideas for clinicians. The report is as follows.
| [1] | Marth, T., Moos, V., Müller, C., et al. (2016) Tropheryma whipplei Infection and Whipple’s Disease. The Lancet Infectious Diseases, 16, E13-E22. https://doi.org/10.1016/S1473-3099(15)00537-X |
| [2] | Ruggiero, E., Zurlo, A., Giantin, V., et al. (2016) Short Article: Relapsing Whipple’s Disease: A Case Report and Literature Review. European Journal of Gastroenterology & Hepatology, 28, 267-270. https://doi.org/10.1097/MEG.0000000000000539 |
| [3] | El-Abassi, R., Soliman, M.Y., Williams, F., et al. (2017) Whipple’s Disease. Journal of the Neurological Sciences, 377, 197-206. https://doi.org/10.1016/j.jns.2017.01.048 |
| [4] | Dolmans, R.A., Boel, C.H., Lacle, M.M., et al. (2017) Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections. Clinical Microbiology Reviews, 30, 529-555. https://doi.org/10.1128/CMR.00033-16 |
| [5] | Biagi, F., Balduzzi, D., Delvino, P., et al. (2015) Prevalence of Whipple’s Disease in North-Western Italy. European Journal of Clinical Microbiology & Infectious Diseases, 34, 1347-1348. https://doi.org/10.1007/s10096-015-2357-2 |
| [6] | Scheurwater, M.A., Verduin, C.M. and Van Dantzig, J.M. (2019) Whipple’s Endocarditis: A Case Report of a Blood Culture-Negative Endocarditis. European Heart Journal Case Reports, 3, 1-6. https://doi.org/10.1093/ehjcr/ytz222 |
| [7] | Obst, W., Von Arnim, U. and Malfertheiner, P. (2014) Whipple’s Disease. Visceral Medicine, 30, 167-172. https://doi.org/10.1159/000363781 |
| [8] | Fenollar, F., Mediannikov, O., Socolovschi, C., et al. (2010) Tropheryma whipplei Bacteremia during Fever in Rural West Africa. Clinical Infectious Diseases, 51, 515-521. https://doi.org/10.1086/655677 |
| [9] | Wiech, T., Reinhard, L., Wulf, S., et al. (2022) Bacterial Infection Possibly Causing Autoimmunity: Tropheryma whipplei and Membranous Nephropathy. Lancet, 400, 1882-1883. https://doi.org/10.1016/S0140-6736(22)02039-6 |
| [10] | Du, Z.M. and Chen, P. (2023) Co-Infection of Chlamydia psittaci and Tropheryma whipplei: A Case Report. World Journal of Clinical Cases, 11, 7144-7149. https://doi.org/10.12998/wjcc.v11.i29.7144 |
| [11] | Puéchal, X. (2013) Whipple’s Disease. Annals of the Rheumatic Diseases, 72, 797-803. https://doi.org/10.1136/annrheumdis-2012-202684 |
| [12] | Schneider, T., Moos, V., Loddenkemper, C., et al. (2008) Whipple’s Disease: New Aspects of Pathogenesis and Treatment. The Lancet Infectious Diseases, 8, 179-190. https://doi.org/10.1016/S1473-3099(08)70042-2 |
| [13] | Edouard, S., Fenollar, F. and Raoult, D. (2012) The Rise of Tropheryma whipplei: A 12-Year Retrospective Study of PCR Diagnoses in Our Reference Center. Journal of Clinical Microbiology, 50, 3917-3920. https://doi.org/10.1128/JCM.01517-12 |
| [14] | Marth, T. (2009) New Insights into Whipple’s Disease—A Rare Intestinal Inflammatory Disorder. Digestive Diseases, 27, 494-501. https://doi.org/10.1159/000233288 |
| [15] | Baloira, A., Nú？ez, M., Tumbeiro, M., et al. (2014) Pulmonary Hypertension Associated with Whipple Disease. European Respiratory Review, 23, 533-536. https://doi.org/10.1183/09059180.00005714 |
| [16] | Touitou, V., Fenollar, F., Cassoux, N., et al. (2012) Ocular Whipple’s Disease: Therapeutic Strategy and Long-Term Follow-Up. Ophthalmology, 119, 1465-1469. https://doi.org/10.1016/j.ophtha.2012.01.024 |
| [17] | Meunier, M., Puechal, X., Hoppé, E., et al. (2013) Rheumatic and Musculoskeletal Features of Whipple Disease: A Report of 29 Cases. The Journal of Rheumatology, 40, 2061-2066. https://doi.org/10.3899/jrheum.130328 |
| [18] | Shao, J., Hassouna, A., Wang, Y., et al. (2022) Next-Generation Sequencing as an Advanced Supplementary Tool for the Diagnosis of Pathogens in Lower Respiratory Tract Infections: An Observational Trial in Xi’an, China. Biomedical Reports, 16, Article No. 14. https://doi.org/10.3892/br.2021.1497 |
| [19] | Feurle, G.E., Junga, N.S. and Marth, T. (2010) Efficacy of Ceftriaxone or Meropenem as Initial Therapies in Whipple’s Disease. Gastroenterology, 138, 478-486. https://doi.org/10.1053/j.gastro.2009.10.041 |
| [20] | Lagier, J.C., Fenollar, F., Lepidi, H., et al. (2014) Treatment of Classic Whipple’s Disease: From in Vitro Results to Clinical Outcome. The Journal of Antimicrobial Chemotherapy, 69, 219-227. https://doi.org/10.1093/jac/dkt310 |
| [21] | Lagier, J.C., Fenollar, F. and Raoult, D. (2014) [Whipple’s Disease and Tropheryma whipplei Infections in Internal Medicine. When to Think about It? How to Treat?]. La Revue De Medecine Interne, 35, 801-807. https://doi.org/10.1016/j.revmed.2014.04.016 |
| [22] | Feurle, G.E., Moos, V., Bl？ker, H., et al. (2013) Intravenous Ceftriaxone, Followed by 12 or Three Months of Oral Treatment with Trimethoprim-Sulfamethoxazole in Whipple’s Disease. The Journal of Infection, 66, 263-270. https://doi.org/10.1016/j.jinf.2012.12.004 |
| [23] | Audoly, G., Fenollar, F., Lagier, J.C., et al. (2016) Deglycosylation of Tropheryma whipplei Biofilm and Discrepancies between Diagnostic Results during Whipple’s Disease Progression. Scientific Reports, 6, Article No. 23883. https://doi.org/10.1038/srep23883 |
